pSivida (PSDV) Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien Study
More News related to PSDV
- Ladenburg Thalmann Initiates Coverage on pSivida (PSDV) with a Buy
- pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009
- Trading Radar for 11/12: Wal-Mart (WMT), Blockbuster (BBI), Nordstrom (JWN), Walt Disney (DIS), Kohl's (KSS) Report
- pSivida Corp. Announces First Quarter 2010 Financial Results Release Date and Conference Call Information
- pSivida Announces Completion of BrachySil(TM) Dose Ranging Study in Pancreatic Cancer
More News related to Corporate News
- Salix Pharma (SLXP) Completes 5.5M Common Offering at $21/Share
- Highlights From LDK's Q3 Conference Call: Sales up 23% Over Prior Quarter; Guides Well Above for Q4
- Highlights From JOBS Q3 Conference Call: Shares Jump on Strong Earnings and Rebound in Market Demand
- Empire Resorts (NYNY) Confirms St. Regis Mohawk Tribe Voted Against Pursing Off-Reservation Gaming in Catskills
- FirstEnergy (FE) Purchases Compressed-Air Development Rights from CAES Development
pSivida Corp (NASDAQ: PSDV) reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien(R). The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Dr. Paul Ashton, CEO of pSivida, said: "We are encouraged with the results we see from this small, 37-patient PK study, particularly as it relates to the safety profile. The lower incidence of elevated IOP with Iluvien in the PK study compared to the higher incidence shown in the data for studies of Retisert(R) (one of our FDA-approved, surgically inserted products which uses the same steroid), is very promising. In this PK study, we see an increase in efficacy in the high dose group and a decrease in efficacy in the low dose group in the results at 18 months as compared to 12 months.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
